Literature DB >> 11602658

Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.

E V Batrakova1, S Li, S V Vinogradov, V Y Alakhov, D W Miller, A V Kabanov.   

Abstract

Pluronic block copolymer, P85, inhibits the P-glycoprotein (Pgp) drug efflux system and increases the permeability of a broad spectrum of drugs in the blood-brain barrier (BBB). This study examines the mechanisms by which P85 inhibits Pgp using bovine brain microvessel endothelial cells (BBMEC) as an in vitro model of the BBB. The hypothesis was that simultaneous alterations in intracellular ATP levels and membrane fluidization in BBMEC monolayers by P85 results in inhibition of the drug efflux system. The methods included the use of 1) standard Pgp substrate rhodamine 123 to assay the Pgp efflux system in BBMEC, 2) luciferin/luciferase assay for ATP intracellular levels, and 3) 1,6-diphenyl-1,3,5-hexatriene for membrane microviscosity. Using 3H-labeled P85 and fluorescein-labeled P85 for confocal microscopy, this study suggests that P85 accumulates in the cells and intracellular organelles such as the mitochondria where it can interfere with metabolic processes. Following exposure of BBMEC to P85, the ATP levels were depleted, and microviscosity of the cell membranes was decreased. Furthermore, P85 treatment decreased Pgp ATPase activity in membranes expressing human Pgp. A combination of experiments examining the kinetics, concentration dependence, and directionality of P85 effects on Pgp-mediated efflux in BBMEC monolayers suggests that both energy depletion (decreasing ATP pool available for Pgp) and membrane fluidization (inhibiting Pgp ATPase activity) are critical factors contributing to the activity of the block copolymer in the BBB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602658

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  69 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 4.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

5.  Effect of pluronic p85 on amino acid transport in bovine brain microvessel endothelial cells.

Authors:  Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-02       Impact factor: 4.147

6.  An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.

Authors:  Brendan M Johnson; William N Charman; Christopher J H Porter
Journal:  AAPS PharmSci       Date:  2002

Review 7.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

8.  Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death.

Authors:  Tianyi M Krupka; David Dremann; Agata A Exner
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

9.  Formulation and characterization of echogenic lipid-Pluronic nanobubbles.

Authors:  Tianyi M Krupka; Luis Solorio; Robin E Wilson; Hanping Wu; Nami Azar; Agata A Exner
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

10.  Transport across the blood-brain barrier of pluronic leptin.

Authors:  Tulin O Price; Susan A Farr; Xiang Yi; Serguei Vinogradov; Elena Batrakova; William A Banks; Alexander V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2010-01-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.